Business Wire

TRAXENS

11.6.2019 09:02:08 CEST | Business Wire | Press release

Share
Traxens Equips Reefer Containers with State-of-the-Art Tracking Telematics Technology for Indonesian Shipping Partner PT Trans Kontainer Solusindo (TKS)

Traxens, a company providing high-value data and services for the supply chain industry, today announces it has equipped the smart reefer containers of a leading Indoniesian NVOCC company, PT TKSolusindo, with its patented Traxens solution.

PT TKSolusindo is a major Non-Vessel Operating Common Carrier (NVOCC) in Indonesia, a country made up of 17,000 islands, where domestic container trades are essential in the daily life of inhabitants. The containers, delivered from the Taicang and Qingdao factories of China International Marine Containers (CIMC), were equipped with Traxens’ smart solutions in only a few days. These now bring PT TKSolusindo, and its clients, full visibility of shipped cargo in the controlled-atmosphere containers throughout all logistical legs of the journey.

Traxens’ solution addresses key challenges in the shipping industry faced by both asset owners and cargo owners. With the support of telematics, asset owners can control costs and develop more agile business problem solving, while cargo owners can easily keep track of their containers, bringing improved business processes and decision making capabilities. Reduced operational costs, improved supply chain efficiency, enhanced security and the opportunity to extend offerings to customers are amongst the key benefits gained through Traxens’ smart solutions. The whole shipping ecosystem, including ports, freight forwarders, insurance and financial institutions, can also benefit from the value-added data gathered by Traxens’ cutting-edge technology.

Traxens offers a comprehensive solution for the reefer industry, which comprises the company’s Reefer Fleet Management and Reefer Door-to-door Monitoring cloud-based applications via the Traxens-Hub, which collects data from Traxens-Box devices installed on containers.

“Traxens’s novel technology is a great addition to the services we provide to our customers, who are keen on staying informed about their cargo’s whereabouts and conditions at all times,” said Glenn Manoppo from PT TKSolusindo. “The reasonable and competitive pricing offered by Traxens were important in our decision when selecting the right partner for the digital transformation of our operations.”

“We are delighted that our reefer tracking technology was chosen by PT. TKSolusindo and we believe that our solution will support the company with the digital transformation of its shipping business,” said Jacques Delort, managing director of Traxens. “We look forward to further co-operations in Asia, a region where domestic and international shipping is crucial for economic success.”

Traxens counts major BCOs among its customers; it also partners with major shipping lines in providing bespoke tracking data for containers.

About PT Trans Kontainer Solusindo (TKSolusindo)

PT TKSolusindo is a subsidiary of an Integrated Cold Chain Solution Company of PT. Kiat Ananda Group, who became the first integrated services provider for refrigerated goods in Indonesia.

PT TKSolusindo specializes in domestic inter-island transport using reefer containers to reach other areas in Indonesia to distribute customers’s goods. The company was set up in 2014, and is now the largest NVOCC in Indonesia with major customers, including international brands such as Unilever, Pizza Hut, Starbucks, Yakult Probiotic, Kentucky Fried Chicken, Greenfield Diary, etc. and local brands such as Hypermart Retail, Hero Retail, Transmart Retail, Charoen Pokphand Indonesia etc. PT TKSolusindo manages more than 500 fleets, generators and trucking.

PT TKSolusindo will develop its international forwarding to support the group trading business in the future.

ABOUT TRAXENS

Traxens generates, collects, consolidates, enriches and transforms logistics asset data into actionable insight for its clients in the maritime, rail and supply chain industries.

The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.

www.traxens.com

Contact:

PRESS CONTACT : Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye